20:34 EST 19th January 2017 | BioPortfolio



152 7 ST
New York
United States of America


Phone: 516-873-8058

News Articles [2410 Associated News Articles listed on BioPortfolio]

PharmaMar leitet entscheidende Phase-III-Studie ATLANTIS zu PM1183 in Kombination mit Doxorubicin bei Patienten mit kleinzelligem Lungenkrebs ein

Madrid (ots/PRNewswire) - PharmaMar (MSE:PHM) kündigte heute den Beginn der zulassungsrelevanten Phase-III der ATLANTIS-Studie an, die zur Bewertung der Wirksamkeit und Sicherheit von PM1183 (Lurbi.....

PharmaMar begins Phase III ATLANTIS trial of PM1183 combined with doxorubicin to treat SCLC

Spanish biopharmaceutical company PharmaMar has initiated the pivotal Phase III ATLANTIS study of PM1183 combined with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicin...

PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in SCLC

(Pharmamar) PharmaMar today announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 in combination with doxorubicin versus topotecan or the combination VCR i...

Atlantis Healthcare - Celebrating 20 years of delivering outcomes-driven, behavior-targeted, global patient support programs

LONDON, Dec. 9, 2016 /PRNewswire/ -- ATLANTIS HEALTHCARE, a pioneer and global leader in health psychology-based patient support programs is celebrating its 20th anniversary today. Atlantis' miss...

The Life Sciences Report Examines Three Shots on Goal in Q4/16 for DURECT Corp.

SAN FRANCISCO, CA--(Marketwired - September 09, 2016) - With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw &...

PharmaMar initiates a phase III ATLANTIS study for small cell lung cancer

PharmaMar Initiates a Pivotal Phase III ATLANTIS Study with PM1183 in Combination with Doxorubicin in Patients with Small Cell Lung Cancer

MADRID, August 2, 2016 /PRNewswire/ -- PharmaMar (MSE:PHM) today announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 (lurbinectedin) in combination with...

Emblem Corp.: Trading Deferred

TORONTO, ONTARIO -- (Marketwired) -- 12/09/16 -- Emblem Corp. announced today that final regulatory approval of the trading date for its shares on the TSXV, originally announced as December 9, 2016,...

Drugs and Medications [0 Results]


PubMed Articles [2709 Associated PubMed Articles listed on BioPortfolio]

Effects of Attention Control Training on Drug Abusers' Attentional Bias and Treatment Outcome.

Attentional bias for drug-related stimuli (Drug-AB) has been shown to play an important role in drug abuse, drug treatment, and relapse. This study sought to retrain Drug-AB using the Drug Attention C...

Changes in Drug Use Among Belgian Higher Education Students: A Comparison Between 2005, 2009, and 2013.

Most drug users initiate illicit drug use during adolescence and young adulthood. Although in the general population a trend towards a decrease in drug use can be seen, patterns of drug use among stud...

Identification of drug- and drug-metabolite immune responses originating from both naïve and memory T-cells.

Both naïve and memory T-cells from drug-naive donors can be stimulated by parent drug and drug haptens. Thus, drug-derived antigens can stimulate naïve T-cells alongside pre-existing memory T-cells ...

Insertion sequences enrichment in extreme Red sea brine pool vent.

Mobile genetic elements are major agents of genome diversification and evolution. Limited studies addressed their characteristics, including abundance, and role in extreme habitats. One of the rare na...

Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats.

Moxifloxacin and rifampicin are all the first line options for treatment of active tuberculosis, which are often combined for the treatment of multi-drug resistance pulmonary tuberculosis in clinic. H...

Clinical Trials [1660 Associated Clinical Trials listed on BioPortfolio]

AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)

Multinational, multicentre, non-pharmacological intervention, cross-sectional and longitudinal study.

Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens

The joint status (knees, ankles) of patients suffering from severe Hemophilia A (too little blood clotting factor VIII in blood) is evaluated in a single magnetic resonance imaging session...

Intra-patient Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT (Optical Coherence Tomography) Follow up

The objective of the study is to evaluate the process of early re-endothelialization of the Coroflex® ISAR Drug-eluting stent compared with the Ultimaster® Drug-eluting stent

Basel Stent Kosten Effektivitäts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions

The investigators hypothesize that in a real-world population undergoing percutaneous coronary intervention (PCI) for de-novo stenoses in small native vessels with a diameter

Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

ATLANTIS is a multicenter, phase IIIb, prospective, open-label, randomized trial. The objective of this study is to demonstrate superiority of a strategy of anticoagulation with apixaban ...

Companies [1224 Associated Companies listed on BioPortfolio]



Atlantis Medical Wellness Center

Benjamin S. Gonzalez, MD, Medical Director, Services: Concierge Medicine, Weight Loss, SmartLipo, Wrinkle Fillers and Botox, Skin Care.


DENTSPLY Implants is the union of two successful and innovative dental implant businesses: DENTSPLY Friadent and Astra Tech Dental. DENTSPLY Implants offers a comprehensive line o...

Interface Biologics

Toronto, Canada – August 26, 2005 - Interface Biologics Inc. announced today the appointment of Richard W. Sullivan to the position of President and Chief Executive Officer of the Company.Mr. Sulliv...


A clinical trial is a research study. Research studies are used to decide how treatments work and how safe they are. While in a study, a person may receive either an investigational drug, a marketed d...

More Information about "ATLANTIS DRUG CORP" on BioPortfolio

We have published hundreds of ATLANTIS DRUG CORP news stories on BioPortfolio along with dozens of ATLANTIS DRUG CORP Clinical Trials and PubMed Articles about ATLANTIS DRUG CORP for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ATLANTIS DRUG CORP Companies in our database. You can also find out about relevant ATLANTIS DRUG CORP Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record